Impact of extent of disease on 1-year healthcare costs in patients who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: retrospective observational cohort study.
B J L KooijmanJudith E K R HentzenC S van der HilstLukas B BeenR J van GinkelP H J HemmerJ M KlaaseS KruijffPublished in: BJS open (2020)
Treatment-related healthcare costs are significantly increased among patients with extensive tumour burden (PCI score 10 or above) who undergo CRS + HIPEC for the treatment of colorectal PM.